Video

Dr. Simon on the Importance of Next-Generation Sequencing in NSCLC

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

George Simon, MD, FACP, FCCP, executive director, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, discusses the importance of next-generation sequencing (NGS) in patients with non–small cell lung cancer (NSCLC).

NGS should be performed for all patients with this disease, especially those with nonsquamous disease, and those who are never-smokers, according to Simon. However, a significant number of patients still do not receive this testing, Simon adds. NGS could provide an opportunity to identify those who would benefit from targeted treatment approaches, Simon concludes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center